From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Progress and Challenges.

ABSTRACT: Mesenchymal stromal cells (MSCs) are an attractive option for cell therapy for type 1 diabetes mellitus (DM). These cells can be obtained from many sources, but bone marrow and adipose tissue are the most studied. MSCs have distinct advantages since they are nonteratogenic, nonimmunogenic and have immunomodulatory functions. Insulin-producing cells (IPCs) can be generated from MSCs by gene transfection, gene editing or directed differentiation. For directed differentiation, MSCs are usually cultured in a glucose-rich medium with various growth and activation factors. The resulting IPCs can control chemically-induced diabetes in immune-deficient mice. These findings are comparable to those obtained from pluripotent cells. PD-L₁ and PD-L₂ expression by MSCs is upregulat

SUBMITTER: Ghoneim MA 

PROVIDER: S-EPMC7667138 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature